Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2011

View Archived Issues

Aliskiren/amlodipine combination shows promise as initial therapy for hypertension

Phase II data presented on sorafenib in GIST and esophageal/gastroesophageal junction cancer

Polypill reduces cardiovascular risk factors in clinical trial

Pfizer develops novel inhibitors of HCV replication

Novel beta-secretase 1 inhibitors claimed at Lilly

Neuropilin-2 promotes epithelial-mesenchymal transition in CRC

CFAK-C4 receives FDA orphan drug status in pancreatic cancer based on preclinical data

First-line TH-302 plus gemcitabine shows promise in advanced/metastatic pancreatic cancer

Receptos begins treatment in phase I trial of RPC-1063 for multiple sclerosis

ALS Biopharma receives ADDF grant to develop HSP70 inducers for AD

Apogenix provides update on phase II APG-101 trial in glioblastoma multiforme

New agents with antidepressant activity claimed by Green Cross

Primary efficacy endpoint met in phase III Gattex trial in short bowel syndrome

DigiFab approved in Canada to treat digoxin toxicity/overdose

New lysophospholipid S1P1 receptor agonists patented

Allergan and MAP Pharma collaborate on Levadex for acute migraine

Vivalis divulges new inhibitors of RNA-directed RNA polymerase

Provectus completes treatment in phase I trial of PV-10 in liver cancer

Nuedexta launched in U.S. for treatment of pseudobulbar affect

Phase I data reported on NRM-8499, a prodrug for Alzheimer's disease

Peregrine fully enrolls phase Ib trial of bavituximab in HIV/HCV coinfection

CHMP recommends approval of BF-200 ALA for actinic keratosis

Onyx initiates rolling NDA for carfilzomib in multiple myeloma

Manhattan Pharma to advance AST-915 to phase II in essential tremor

Phase III trial of Cytotect for prevention of congenital CMV infection to continue

Faron and Maruishi to collaborate on Traumakine program in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...